Valbiotis’ scientific publications

TOTUM•854 prevents L-NAME induced arterial hypertension in mice

TOTUM•63: a new promising approach for the management of obesity and risk reduction for developing Type 2 Diabetes

TOTUM•63 reduces body weight and improves insulin sensitivity in obese mice through pleiotropic effects on various metabolic organs

TOTUM•63 lowers fasting glycemic in subjects with prediabetes: a Phase II clinical trial

American Diabetes Association 2020 – 80th scientific sessions -TOTUM•63 lowers fasting glycemia in subjects with prediabetes: a phase II clinical trial

European Association for the Study of Diabetes (EASD) annual congress 2019 – TOTUM•63 corrects levels of hormones associated to type 2 diabetes.

American Diabetes Association 2019 – 79th scientific sessions – TOTUM•63 lowers adipose tissue inflammation

American Association for the Study of Liver Diseases (AASLD), 2018 Congress – TOTUM•63 reduces hepatic steatosis

European Association for the Study of Diabetes (EASD), 2018 Congress, Berlin (Germany) – TOTUM•63 multi-target mode of action

Keystone Symposia 2018, Banff (Canada) – LpD64 reduces intestinal dysbiosis associated with metabolic disorders

Keystone Symposia 2018, Keystone (USA) – TOTUM•63 acts on intestinal microbiota

International Diabetes Federation, 2017 Congress, Abu Dhabi (UAE) – TOTUM•63 reduces hepatic steatosis

Cell Symposium 2017, San Diego (USA) – LpD64, in vivo effects on lipids metabolism

American Diabetes Association, 2017 Congress, San Diego (USA) – TOTUM•63, results of the Phase I/II clinical study

Société Francophone du Diabète, 2017 Congress, Lille (France) – TOTUM•63, preclinical data on insulin resistance and fat mass

American Diabetes Association, 2016 Congress, New Orleans (USA) – TOTUM•63, preclinical data on glucose metabolism

Keystone Symposia 2016, Keystone (USA) – LpD64, preclinical data on obesity